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Abstract
Background: Vaginal atrophy (VA) is the thinning of the vaginal epithelial lining, typically the result
of lowered estrogen levels during menopause. Some of the consequences of VA include increased
susceptibility to bacterial infection, pain during sexual intercourse, and vaginal burning or itching.
Although estrogen treatment is highly effective, alternative therapies are also desired for women
who are not candidates for post-menopausal hormone therapy (HT). The ovariectomized (OVX)
rat is widely accepted as an appropriate animal model for many estrogen-dependent responses in
humans; however, since reproductive biology can vary significantly between mammalian systems,
this study examined how well the OVX rat recapitulates human biology.
Methods: We analyzed 19 vaginal biopsies from human subjects pre and post 3-month 17β-
estradiol treated by expression profiling. Data were compared to transcriptional profiling
generated from vaginal samples obtained from ovariectomized rats treated with 17β-estradiol for
6 hrs, 3 days or 5 days. The level of differential expression between pre- vs. post- estrogen
treatment was calculated for each of the human and OVX rat datasets. Probe sets corresponding
to orthologous rat and human genes were mapped to each other using NCBI Homologene.
Results: A positive correlation was observed between the rat and human responses to estrogen.
Genes belonging to several biological pathways and GO categories were similarly differentially
expressed in rat and human. A large number of the coordinately regulated biological processes are
already known to be involved in human VA, such as inflammation, epithelial development, and EGF
pathway activation.
Conclusion: At the transcriptional level, there is evidence of significant overlap of the effects of
estrogen treatment between the OVX rat and human VA samples.
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Background
In many women, declining estrogen levels at menopause
lead to a number of physiological changes, including vas-
omotor instability (hot flushes), mood swings, decreased
libido, vaginal atrophy (VA), serum lipid changes and the
increased risk of developing osteoporosis. While proges-
tin and/or estrogen therapy are clinically proven to amel-
iorate some of these symptoms, these medications are
contraindicated in some populations, and other women
choose not to take them. Because of these issues, recent
work has focused on developing more specific, and in
many cases, nonhormonal alternatives to traditional post-
menopausal hormone therapy. These alternatives have
focused largely on reduction of hot flushes [1,2] and the
treatment/prevention of osteoporosis [3-5].
VA affects up to 40% of postmenopausal women, with
those with an active sex life being more apt to complain of
symptoms (see [6] for review). Its hallmarks are thinning
epithelia and increased vaginal pH. Symptoms include
dryness, burning, itching, decreased lubrication during
sexual stimulation and painful intercourse. In extreme
cases the epithelium is absent and adhesions form in the
vaginal vault, preventing clinical exams and drainage of
fluid [7]. Currently, estrogens (both systemically and
locally administered) are the only approved medical ther-
apies for treating VA. Lubricants can relieve some of the
symptoms of VA, but do not treat the underlying cause.
Despite the fact that the vagina is a classic estrogen-
responsive organ, it has received little attention compared
to the adjacent uterus. Uterine responses to estrogens on
the reproductive cycle have been well-characterized and
several expression profiles have been generated [8-10],
but no analogous studies have been performed on the
vagina, aside from a recent report that examines the vagi-
nal effects of neonatal diethylstilbestrol exposure [11].
Our ultimate goal is to develop nonhormonal therapies
for VA in order to provide additional treatment options
for post-menopausal women. Key to evaluating new com-
pounds is the development of preclinical animal models,
preferably in the rat or mouse. Drawing on the extensive
studies of the rat uterine response to estrogens for the
development of selective estrogen receptor modulators
(SERMs) [12-15], we constructed an analogous model of
rat vaginal responses. This report details the time course of
mRNA changes elicited by 17β-estradiol in the ovariect-
omized (OVX) rat vaginal vault and compares these
responses to those seen in the human vaginal epithelium
after three months of 17β-estradiol patch therapy.
Methods
Animals care/tissue collection/dosing
All animal studies were approved by the Institutional Ani-
mal Care and Use Committee of Wyeth Research, Colle-
geville, PA and were conducted in accordance with
Association for the Assessment and Accreditation of Lab-
oratory Animal Care (AAALAC) guidelines. Sprague Daw-
ley rats (Taconic, Germantown NY) were OVX at 8 weeks
of age and rested for about 1 week before administration
of daily subcutaneous doses of 17β-estradiol (20 μg/kg)
or vehicle (50% DMSO/50% 1× Dulbecco's PBS). Ani-
mals were euthanized after 6 hrs, 3 days and 5 days of
treatment. For the 3- and 5-day timepoints, animals were
euthanized 6 hours after the last dose. At necropsy, the
vaginal vault was excised and trimmed of adherent tissue
(e.g. the urethra). Typically, organs were trimmed just
below the cervix and above the external orifice of the
vagina before flash freezing in liquid nitrogen.
For the studies using betacellulin, 8-week-old female
Sprague Dawley rats were OVX and allowed to recover
from surgery for 10 days prior to treatment. Rats were
dosed intravaginally for 5 days with mouse betacellulin
(200 nM; R&D Systems, Minneapolis MN) once daily
using a carbomer-934P-based vehicle (pH 7.0) and a 0.5
inch long, 18 gauge ball-tipped gavage needle. Following
euthanasia by CO2 asphyxiation and pneumothorax, the
vaginal vault was removed, flattened on an index card and
fixed in 10% buffered formalin (VWR International, West
Chester, PA) for 16–72 hours. Vaginas were equilibrated
in 15% sucrose for 3 hours prior to embedding in OCT
(Sigma, St Louis MO) and cryosectioning. Ten micron sec-
tions were stained with hematoxylin and eosin (both
from Sigma) for histological analysis.
Human tissue collection
A clinical study was initiated to collect 3 mm vaginal
biopsy specimens from post-menopausal women clini-
cally diagnosed with VA. The diagnosis of VA was con-
firmed by a vaginal maturation index (VMI) containing
≤5% superficial cells and vaginal pH > 5.0. Patients were
treated for 3 months with 17β-estradiol, delivered via a
skin patch, at a dose of 0.05 mg/day. All 19 subjects had
increased VMI (>5%) and/or reduced pH (< or = 5) fol-
lowing treatment. Vaginal biopsies were collected on day
1 prior to the initiation of treatment with 17β-estradiol
and on the last day of treatment (day 85). Samples were
immediately frozen on dry ice and stored at -80°C until
RNA isolation. This study was conducted at the Ohio State
University, Division of Clinical Pharmacology (Colum-
bus, Ohio). Written informed consent was obtained from
all subjects prior to any study-related procedure. Western
Institutional Review Board (Olympia, WA) approved the
protocol and informed consent. The details of the clinical
analyses have been reported elsewhere [16].BMC Medical Genomics 2008, 1:27 http://www.biomedcentral.com/1755-8794/1/27
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RNA isolation
Each rat vagina was homogenized in 3 mL of TRIzol rea-
gent (Invitrogen, Carlsbad CA) using a Polytron PT3000
grinder (Brinkmann, Westbury NY) at a setting of 12–15
for 1 min. Subsequent RNA extraction was as described
previously [17]. For human samples, RNA extraction was
performed according to a modified RNeasy mini kit
method. (Qiagen, Valencia, CA) [16].
qRT-PCR analysis
ComplementaryDNA was amplified from 50 ng total RNA
with the Ovation RNA Amplification System (Nugen, San
Carlos CA). Real-time PCR reactions (qRT-PCR) were con-
ducted using the TaqMan®  Universal PCR Master Mix
(Applied Biosystems). Forward and reverse primers (10
μM) and 20 μM labeled probe was mixed with 2× PCR
master mix in a total volume of 15 ul and added to 50 ng
cDNA in final reaction volume of 25 μl.
PCR reactions were run on an automated fluorometer
(ABI Prism 7000 Sequence Detection System, Applied
Biosystems) in a 96-well format. PCR conditions for all
reactions were as follows: 1 cycle of 50°C for 2 min., 95°C
for 10 min. followed by 40 cycles of 95°C for 15 sec. and
60°C for 1 min. Relative expression was determined by
using the CT method (Pontius et al., 2003) using Sequence
Detector software, version 1.6.3. Complementary DNAs
of each sample were evaluated in triplicate. Results were
normalized to a control gene, SFSR10 RNA, which has
been shown to have very consistent expression across all
patient samples by microarray analysis [16].
The primer sequences for each transcript are as follows:
BTC: forward primer, 5'-GGTGTGAGAGAGTTGACTT-
GTTTTACC-3'; reverse primer, 5'-TGCTATCAAACAAAT-
CACCAGAATC-3'; probe, 5'-TGTCCTCTGTCTCCTCT-3'
SFSR10: forward primer, 5'-AAGGGAACACTATACCTGT-
CATGGA-3'; reverse primer, 5'-GGTAAGCAAAGGACCT-
GAAAATAATATT-3'; probe, 5'-AAGACTTTGCCTGTTCAT-'
Microarray processing
For rat vaginal samples, 5 μg of total RNA were used to
generate biotin labeled cRNA using an oligo T7 primer in
a reverse transcription reaction followed by in vitro tran-
scription reaction with biotin labeled UTP and CTP. Ten
μg of cRNA were fragmented and hybridized to RAE230A
and RAE230B arrays (Affymetrix, Santa Clara, CA). For
human biopsies, RNA was labeled using Ovation™ Biotin
System (Nugen, San Francisco, CA). Labeled cDNA (2.5
μg) was fragmented and hybridized to HGU133 Plus 2.0
arrays (Affymetrix, Santa Clara, CA) [16]. Hybridized
arrays were stained according to manufacturer's protocols
on a Fluidics Station 450 and scanned on an Affymetrix
scanner 3000. All array images were visually inspected for
defects and quality. Arrays with excessive background, low
signal intensity, or major defects within the array were
eliminated from further analysis. Signal values were deter-
mined using Gene Chip Operating System 1.0 (GCOS,
Affymetrix). For each array, all probe sets were normalized
to a mean signal intensity value of 100. The default GCOS
statistical values were used for all analysis. Signal values
and absolute detection calls were imported into Genesis
2.0 (GeneLogic, Gaithersburg, MD) for analysis. The com-
plete data set is available at the Gene Expression Omnibus
as GSE11622 [18].
Determination of probe sets corresponding to homologous 
gene pairs
Mapping of RAE230 to HGU133 plus 2.0 probe sets was
based on NCBI's Homologene (clusters of orthologous
genes). First, all qualifiers were annotated with unigene
accession numbers through BioExpress (GeneLogic).
These accession numbers then were used to map ortholo-
gous sequences through NCBI Homologene [19]. Com-
monly one probe set from one species maps to multiple
probe sets from a second species. To resolve multiple
mappings, clusters of orthologous probe sets were gener-
ated as follows. For each human probe set, all correspond-
ing rat probe sets were identified and grouped into a
"cluster". Human probe sets that map to the same set of
rat probes were clustered. For each human cluster, the cor-
responding locuslink ID(s) were identified. Clusters with
multiple Locuslink ID annotations were discarded.
Approximately 10% of the human probe sets clustered to
multiple Locuslink IDs. Clustering identified 9093
groups, spanning 22460 human probe set IDs and 13219
rat probe set IDs. Each cluster was annotated (assigned
GO/KEGG etc categories) based on the human Locuslink
ID in that cluster.
Identification of regulated genes
Identification of estrogen-regulated genes was done in
two independent ways. In the first method, probe sets
were considered estrogen regulated if the following condi-
tions were met: 1) A gene was expressed greater than 50
signal units, 2) the percentage of samples with a Present
(P) call as determined by GCOS default settings was
greater than or equal to 66% in any sample condition, 3)
the fold change between all estrogen treated and vehicle
treated samples was at least 1.7, and 4) the p-value based
on an Wilcoxon t-test was ≤0.01 (rat) or based on a Wil-
coxon paired test was <0.01 (human). Over 5300 rat
probe sets and 1668 human probe sets met these condi-
tions. The second method used the 9093 clusters identi-
fied above. Arrays were subjected to a Loess
transformation and the CyberT-statistics were calculated.
False discovery rate estimates (q-values) were estimated
using a null distribution of CyberT's from permuted data.BMC Medical Genomics 2008, 1:27 http://www.biomedcentral.com/1755-8794/1/27
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Identification of significantly regulated gene sets
Statistical identification of significantly regulated biologi-
cal pathways was implemented using a modified
approach of Tian et al. [20]. 7798 gene sets were tested in
the sigpathway analysis. These were derived from the fol-
low sources: 1) GO annotations (from Affymetrix) [21],
2) KEGG/GenMAPP annotations (from Affymetrix) [21],
3) Functional categories (from MSigDB), 4) Genes that
are located in close proximity along the chromosome
(from MSigDB), 5) Genes containing instances of a regu-
latory motif of interest (from MSigDB), and 6) Genes that
are co-regulated with a given gene in a variety of datasets
(from MSigDB). Gene sets from MSigDB were derived
from pathway databases (Biocarta, KEGG, and BioCyc)
and pathway-specific microarray annotations [22], as well
as >5,000 gene sets from Gene Ontology. Only gene sets
in which the number of genes was greater or equal to 10
and less than or equal to 400 were used for further analy-
sis. Each gene set was assigned a score of differential
expression between two conditions (essentially, the sum
of t-statistics for each gene within the set), and the false
discovery rate (Q) associated with this score was calcu-
lated via two separate permutation tests (permuting gene
labels (Q1) and sample labels (Q2)). A gene set was con-
sidered significant if its two false discovery rates are below
0.15 (Q1 <= 0.15 and Q2 <= 0.15) for all 4 comparisons.
45 gene sets passed these criteria.
Results
Estrogen-responsive genes in the rat vaginal vault
Eight-week-old rats were OVX and rested for about 1 week
to mimic the loss of estrogen commonly seen in postmen-
opausal women. Animals were then treated with 17β-
estradiol for 6 hrs, 3 days or 5 days following surgery. Rat
vaginal vault tissue was collected, mRNA prepared and
estrogen regulated genes identified through transcrip-
tional profiling. Three time points were chosen for analy-
sis to capture the range of responses to estradiol: six hours,
representing the early phase of the estrogen-signaling cas-
cade, five days, at which time vaginal histology is com-
pletely restored, and three days, an intermediate time
point. We found the vaginal tissue to be extremely respon-
sive to 17β-estradiol, with over 5300 unique probe sets
(~17% of the probe sets monitored) showing differential
expression in at least one time point (fold change > 1.7, p-
value <0.01, Table 1). Surprisingly, a majority (> 63%) of
these genes were down regulated after estradiol treatment.
Expression of genes with similar expression patterns in both human and rat Figure 1
Expression of genes with similar expression patterns in both human and rat. Messenger RNA levels for (A) keratin 
5b, (B) Spink5, (C) Sprr1a, (D) FLJ21511, (E) Desmoglein 5 and (F) Abhd5 are shown for each individual treatment.








+
X
P
D
Q

S
U
H

(

+
X
P
D
Q

S
R
V
W

(

5
D
W

Y
H
K


K
U
5
D
W

9
H
K


G
D
\
V
5
D
W

9
H
K



G
D
\
V
5
D
W

(



K
U
V
5
D
W

(




G
D
\
V
5
D
W

(




G
D
\
V






































$% &
'( )
+
X
P
D
Q

S
U
H

(

+
X
P
D
Q

S
R
V
W

(

5
D
W

Y
H
K


K
U
5
D
W

9
H
K


G
D
\
V
5
D
W

9
H
K



G
D
\
V
5
D
W

(



K
U
V
5
D
W

(




G
D
\
V
5
D
W

(




G
D
\
V
+
X
P
D
Q

S
U
H

(

+
X
P
D
Q

S
R
V
W

(

5
D
W

Y
H
K


K
U
5
D
W

9
H
K


G
D
\
V
5
D
W

9
H
K



G
D
\
V
5
D
W

(



K
U
V
5
D
W

(




G
D
\
V
5
D
W

(




G
D
\
V
Table 1: Number of probe sets regulated by 17-β estradiol in rat 
vaginal tissue
Up regulated Down Regulated Total
Genes regulated at 5 days 1305 2395 3700
Genes regulated at 3 days 1513 2364 3877
Genes regulated at 6 hours 631 1155 1786BMC Medical Genomics 2008, 1:27 http://www.biomedcentral.com/1755-8794/1/27
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We find regulation of many known estrogen target genes
[23-25] including calbindin-3 (77 fold), kallikrein 6 (33
fold), arginase 1 (27 fold), adenosine deaminase (14.6
fold), progesterone receptor (3.8 fold), cathepsin D (2.3
fold) and trefoil factor (2.1 fold) that are up regulated in
rat vagina tissue.
Differentially expressed genes in the human
Human vaginal biopsy specimens from 19 postmenopau-
sal women clinically diagnosed with VA were collected.
Participants in the study were treated for 3 months with
17β-estradiol, delivered via a skin patch, with vaginal
biopsies collected prior to the initiation of treatment and
on the last day of treatment. Microarray analysis of these
biopsies resulted in 1668 genes regulated by at least 1.7
fold (772 up regulated and 896 down regulated, Wilcoxon
paired t-test p < 0.01). The details of this analysis are
described elsewhere [16]. Like the rat vaginal samples, we
find the human vagina to be very responsive to estradiol
although we see fewer genes regulated in the human sam-
ples. The difference in the number of significant genes
could be the result of several factors, such as the greater
variability (in genetics, age, etc) amongst the human
patients in comparison to the inbred rats, or the fact that
the human biopsies contained primarily epithelial cells,
while the rat samples were the entire vaginal vaults.
Mapping of RAE230 to HGU133 Plus 2.0 probe sets
Our goal was to determine how closely the OVX rat model
of VA mimics the human disorder. Our first step required
Table 2: Top coregulated clusters of genes
Human cluster Rat cluster
Gene Symbol Gene Description t* q** t* q**
DSG1 desmoglein 1 6.5 0 12.8 0
GADD45A growth arrest and DNA-damage-inducible, alpha 6.8 0 5.1 0
HMGCS1 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 5.2 0.0002 9.5 0
SC4MOL sterol-C4-methyl oxidase-like 4.1 0.0025 9.2 0
FAM46B family with sequence similarity 46, member B 2.4 0.0896 10.2 0
CRABP2 cellular retinoic acid binding 2 4.0 0.0029 12.6 0
CBR3 carbonyl reductase 3 5.2 0.0002 6.5 0
SLURP1 secreted LY6/PLAUR domain 4.4 0.0014 9.1 0
ATP6V1D ATPase, H+ transporting, lysosomal, V1 subunit D 4.4 0.0011 9.5 0
KLF4 Kruppel-like factor 4 4.3 0.0016 7.5 0
GPT2 glutamic pyruvate transaminase 3.3 0.0175 8.7 0
CLIC3 chloride intracellular channel 3 2.8 0.0481 9.2 0
MAL2 T-cell differentiation protein 2 4.2 0.002 7.9 0
S100A10 S100 calcium binding protein A10 3.7 0.0067 9.1 0
FLJ12151 hypothetical protein FLJ12151 4.7 0.0006 6.4 0
HMGCR 3-hydroxy-3-methylglutaryl-Coenzyme A reductase 4.3 0.0016 5.7 0
MAFB musculoaponeurotic fibrosarcoma homolog B 3.7 0.0071 5.7 0
RAB10 RAB10, member RAS oncogene family 3.5 0.0119 8.7 0
SERPINB2 serine proteinase inhibitor, clade B 2 3.4 0.0137 7.9 0
SQLE Squalene epoxidase 2.8 0.0471 8.4 0
AVPI1 arginine vasopressin-induced 1 4.4 0.0012 6.8 0
AIM1L absent in melanoma 1-like 2.6 0.0625 8.8 0
BNIP3 BCL2/adenovirus E1B 19 kDa interacting protein 3 6.3 0 5.2 0
BZW1 basic leucine zipper and W2 domains 1 3.9 0.0038 6.3 0
LOC58489 hypothetical protein 2.9 0.0386 8.6 0
AACS acetoacetyl-CoA synthetase 4.1 0.0024 4.7 0
MGC13102 hypothetical protein MGC13102 3.7 0.0068 7.6 0
ETF1 eukaryotic translation termination factor 1 2.8 0.0438 8.0 0
C4.4A GPI-anchored metastasis-associated protein homolog 3.0 0.0327 9.2 0
HMOX1 heme oxygenase 1 5.5 0.0002 5.1 0
KCTD11 K+ channel tetramerisation domain containing 11 4.7 0.0006 3.8 0
CDK7 cyclin-dependent kinase 7 5.9 0.0002 2.4 0.02
JUNB jun B proto-oncogene 3.5 0.0113 5.7 0
RIOK3 RIO kinase 3 4.7 0.0006 4.6 0
ME1 malic enzyme 1 4.6 0.0007 4.6 0
YWHAZ tyrosine 3-monooxygenase activation protein, zeta 2.5 0.0779 9.0 0
t* Average t-statistic
q** Average q-valueBMC Medical Genomics 2008, 1:27 http://www.biomedcentral.com/1755-8794/1/27
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identifying pairs of orthologous genes, and finding the rat
(RAE230) and human (HG-U133 plus 2.0) probe sets cor-
responding to them. In order to do this, probe set annota-
tions and ortholog assignments were obtained from
BioExpress 2.0 (GeneLogic) and NCBI Homologene,
respectively. When multiple probe sets on a chip query the
same gene, a per-gene score of differential expression was
calculated by taking the average t-statistic for those probe
sets (see Methods for details). In total, we identified 9093
pairs of orthologous genes that were represented on both
chipsets, and for each pair, calculated a score of differen-
tial expression for each rat and human. These 9093 pairs
spanned 22460 human probe set IDs and 13219 rat probe
set IDs. Each orthologous gene pair was annotated
(assigned GO/KEGG categories) based on the human
LocusLink ID for that pair. Of the 9093 pairs, 1102 (554
up/548 down, q < 0.05) were regulated in the human data
set; of these, 707 (349 up/358 down, q < 0.05) were regu-
lated in the rat after 5 days treatment and 558 (79%, 285
up/273 down) were coordinately regulated in both spe-
cies. The top co-regulated genes include desmoglein,
growth arrest and DNA-damage-inducible alpha, 3-
hydroxy-3-methylglutaryl-Coenzyme A synthase 1 and
ATPase, H+ transporting, lysosomal 34 kDa, V1 subunit D
and expression of these genes is depicted in Figure 1. Table
2 and Table 3 contain the list of top co-regulated genes for
induced and repressed genes.
Table 3: Top coregulated clusters of genes
Human cluster Rat cluster
Gene Symbol Gene Description t* q** t* q**
TXNIP thioredoxin interacting protein -5.5 0.0002 -12.5 0
RBP1 retinol binding protein 1, cellular -4.2 0.0021 -15.1 0
IGFBP3 insulin-like growth factor binding protein 3 -4.6 0.0007 -10.0 0
IFITM3 interferon induced transmembrane protein 3 (1–8 U) -5.2 0.0002 -9.0 0
DHRS8 dehydrogenase/reductase (SDR family) member 8 -5.4 0.0002 -5.6 0
LDHB lactate dehydrogenase B -4.6 0.0006 -6.1 0
LAPTM4B lysosomal associated protein transmembrane 4 beta -4.5 0.0008 -8.3 0
MUC1 mucin 1, transmembrane -5.7 0.0002 -5.2 0
SFRP2 secreted frizzled-related protein 2 -5.4 0.0002 -5.8 0
IFITM1 interferon induced transmembrane protein 1 (9–27) -4.2 0.0019 -6.8 0
CD74 CD74 antigen -4.3 0.0015 -8.2 0
LR8 LR8 protein -3.6 0.0076 -7.6 0
B2M beta-2-microglobulin -4.1 0.0025 -8.0 0
PPP1R1B protein phosphatase 1, regulatory (inhibitor) subunit 1B -4.8 0.0006 -6.1 0
PRKACB protein kinase, cAMP-dependent, catalytic, beta -5.2 0.0003 -4.2 0
TSPAN3 tetraspanin 3 -4.4 0.0014 -6.5 0
PROM1 prominin 1 -2.8 0.0452 -9.0 0
TMC4 transmembrane channel-like 4 -3.8 0.0045 -8.0 0
ITM2C integral membrane protein 2C -3.0 0.0343 -8.0 0
DHRS3 dehydrogenase/reductase (SDR family) member 3 -3.6 0.0079 -5.9 0
ITM2B integral membrane protein 2B -2.5 0.0778 -9.6 0
VIM vimentin -2.7 0.0503 -9.6 0
NPC2 Niemann-Pick disease, type C2 -4.0 0.0029 -6.5 0
AXL AXL receptor tyrosine kinase -4.4 0.0012 -4.9 0
HLA-DRA major histocompatibility complex, class II, DR alpha -3.3 0.0153 -8.5 0
EEF1A1 Eukaryotic translation elongation factor 1 alpha 1 -4.1 0.0023 -5.1 0
FOXQ1 forkhead box Q1 -3.5 0.0116 -6.1 0
IFNGR1 interferon gamma receptor 1 -2.5 0.0745 -8.5 0
IGFBP7 insulin-like growth factor binding protein 7 -3.4 0.0138 -7.2 0
RNASET2 ribonuclease T2 -3.0 0.032 -7.4 0
SAT spermidine/spermine N1-acetyltransferase -3.7 0.0073 -7.6 0
BHLHB3 basic helix-loop-helix domain containing, class B, 3 -5.8 0.0002 -2.3 0.04
SELENBP1 selenium binding protein 1 -4.0 0.0033 -4.8 0
C11orf8 chromosome 11 open reading frame 8 -5.0 0.0004 -3.6 0
LSP1 lymphocyte-specific protein 1 -4.9 0.0004 -2.9 0
KRT19 keratin 19 -3.3 0.0 -10.1 0
t* Average t-statistic
q** Average q-valueBMC Medical Genomics 2008, 1:27 http://www.biomedcentral.com/1755-8794/1/27
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Correlation between Rat and Human Data
In order to compare human and rat vaginal responses to
17β-estradiol we first constructed a per-gene score of dif-
ferential expression ("tgene"), by computing the average t-
statistic over the probe sets querying a given gene for each
of the four datasets (human data, and 3 rat time points).
When these tgene values for orthologous genes were com-
pared via scatterplot, we observed an overall positive cor-
relation between the four datasets (Figure 2). Pearson
correlation coefficients between human and rat were 0.13,
0.30 and 0.33 for the 6 hour, 3 day and 5 day rat data,
respectively. This level of positive correlation was statisti-
cally significant (see Methods), suggesting that the two
species have a similar response to estradiol. Furthermore,
it clearly showed that the 5-day time point is more corre-
lated to the human data than is either the 3-day or 6 hour
time points. Since the human study involved treatment
for 3 months, it likely represents an end stage while the
lower correlation to the 6 hr and 3-day time point suggests
that these likely represent transition stages. Therefore the
5-day time point was used for further comparisons with
the human data.
Sigpathway analysis
We applied a modified version of the Sigpathway algo-
rithm [20] to identify gene sets or pathways significantly
regulated by estradiol in either species. This method
detects the differential expression of pre-defined gene sets.
A gene set is simply defined as a collection of genes shar-
ing a common biological attribute, such as Gene Ontol-
ogy annotation, signaling pathway membership, or co-
expression in another transcriptional profiling dataset.
We tested the gene sets from the MSigDB database (ver-
sion 1.0, Whitehead Institute)[26] for differential expres-
sion after estradiol treatment. The analysis was run on the
tgene values for the 9039 genes with orthologs across spe-
cies and resulted in 45 gene sets that were significantly reg-
ulated in both the human biopsy samples and the rat 5
day treatment samples (Figure 3 and Table 4). Upregu-
lated gene sets include pathways such as cholesterol bio-
synthesis, steroid metabolism, lysosome function, and
epidermis and ectoderm development biosynthesis.
Down regulated genes are representative of the TGF-beta
signaling pathway, complement activation and matrix
metalloproteinases. Examples of two estradiol-sensitive
pathways, shown as cumulative distribution plots, are
shown in Figure 4. The full list of co-regulated pathways
can be found in Table 4.
Gene set correlation Figure 3
Gene set correlation. A scatterplot of the average t-statis-
tic of estradiol treated vaginal tissue compared to untreated 
vaginal tissue for each of the human gene sets compared to 
the average t-statistic for each of the rat gene sets. Each 
point represents a distinct gene set. A positive correlation is 
seen suggesting many of the gene sets are coordinately regu-
lated. Gene sets in the upper right and lower left corners 
represent gene sets that are significantly regulated in both rat 
and human.
í í   




í

í

í

í
5DWGD\
Q
D
P
X
+
Correlation of t-statistics Figure 2
Correlation of t-statistics. T-statistics were calculated for 
estrogen treated samples vs. control (see Methods) for the 
9093 clusters of probe sets for both human and rat tissues. 
Scatter plots of the t-statistic for each gene are shown. Num-
bers represent correlation coefficients for each respective 
pair of samples.
5DW
K





í





í

5DW
G


5DW
G





í



+XPDQ
        BMC Medical Genomics 2008, 1:27 http://www.biomedcentral.com/1755-8794/1/27
Page 8 of 12
(page number not for citation purposes)
Experimental validation of betacellulin
We hypothesized that genes co-regulated in both species
are more likely to be important for estrogen signaling and
the mitogenic effects seen with estrogen treatment. Fur-
ther experiments were conducted in the OVX rat model
for specific genes of interest, first to validate the microar-
ray results, and second, to determine if the gene product
can provide an estrogen-like response. Betacellulin (BTC)
is one such gene that was chosen for further validation
(Figure 5A). BTC is a widely expressed member of the EGF
superfamily and is a known mitogen for a variety of cell
types (see [27] for review). It has long been known that
EGF can activate ERα and that these signaling pathways
converge (see [28] for review), thus this protein was a
good candidate for further evaluation.
BTC expression levels increase significantly after estrogen
treatment in both rat (Figure 5B) and human. Because
expression levels of BTC on the human array were rela-
tively low, qRT-PCR was used to confirm regulation in the
human (Figure 5C). BTC is upregulated in 14 of the 17
patients examined. Therefore, it appears that BTC has sim-
ilar regulation in rat and human. Administration of BTC
protein intravaginally in OVX rats results in a thickening
and proliferation of the vaginal epithelium as detected by
histology (Figure 5A, panel BTC). BTC administration was
also noted in some cases to induce abnormal vaginal epi-
thelial proliferation (Figure 5, panel BTC-abn) consistent
with its mitogenic role.
Discussion
The current animal model of VA involves the use of OVX
rats. Since the ovaries are the major source of estrogens,
removal of the ovaries mimics an estrogen-deprived state.
It is well documented that as women enter menopause,
the levels of circulating estrogens decrease, resulting in a
number of physiological changes, including VA. VA can be
reversed through estrogen hormone replacement, suggest-
ing that loss of estrogen is the major factor leading to VA.
OVX animal systems mimic many human postmenopau-
sal systems, in both phenotype and histology, and have
been well-characterized models for studying these
changes. We have taken a systematic molecular approach
to determine if the animal model for VA is similar to the
human disorder at the transcriptional level.
We have used this experiment to identify genes and path-
ways that are estrogen regulated in both rat and human
vaginal tissue. It is important to note that there are differ-
ences in the experimental conditions. First, we evaluated
the animal model after 6 hours, 3 or 5 days of treatment.
At the 5-day time point, the vaginal epithelium has fully
responded to estrogen treatment by histology. We have
not, however, compared the transcriptional profiles of
normal vaginal tissue across the estrus cycle to vaginal tis-
sue from an OVX animal treated with an estrogen. It is
possible that there are differences between the estrogen
treated, OVX-animals vs. ovary-intact animals. Second,
there have been no comparable studies done in postmen-
opausal women to determine the time course of histolog-
ical changes following estrogen therapy. As a result, we
Cumulative distribution plots Figure 4
Cumulative distribution plots. Plotted is the normalized t-statistics for differential expression on the x-axis plotted against 
the fraction of the gene set that has that x-value or lower on the y-axis. Gene sets that are shifted away from the plot of the 
entire data set are considered to be significant. (A) Genes involved in TGFβ signaling are down regulated in both species. (B) 
Genes involved in cholesterol biosynthesis are up regulated in both species.
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chose to look at a time point (3 months) in which we
would be sure to see a significant effect. Due to differences
in collection times, it is quite possible that we are looking
at slightly different molecular endpoints between the
human and the OVX rat. Third, it is also worth noting that
the tissues being profiled are different. In the animal
model we examined the entire vaginal vault, while the
human samples contained primarily the vaginal epithelia.
Estrogen response likely depends on the cell type compo-
sition.
Furthermore, because the rat transcriptome is less well
annotated than human, inaccurate or incomplete map-
pings between the two chipsets may result. Our methods
involved grouping together human probe sets mapping to
the same gene, calculating the average of their t-statistics,
and comparing this value to the average t-statistic for the
orthologous rat gene. This procedure was chosen after
observing that this metric yielded greater agreement
between human and rat in a kidney-vs-liver comparison
(see below). However, averaging the results for probe sets
Table 4: Enriched pathways of estrogen regulated genes in human and rat
Gene Set Rat T1* Human T1*
Cholesterol_Biosynthesis // Genmapp 6.55 3.91
Cellular Lipid Metabolism // GO:0044255 2.21 3.67
Mitotic Cell Cycle // GO:0000278 2.8 3.14
Cysteine Protease Inhibitor Activity // GO:0004869 2.94 3.02
Small Protein Conjugating Enzyme Activity // GO:0008639 2.34 2.85
Epidermis Development // GO:0008544 5.44 2.65
Steroid Metabolism // GO:0008202 3.23 2.65
Ubiquitin Conjugating Enzyme Activity // GO:0004840 2.3 2.55
Tgf_Beta_Signaling_Pathway: Biocarta -3.09 -2.54
Complement_Activation_Classical -2.29 -2.57
Chr3Q13: Cytogenetic Band -2.36 -2.6
Complement_Activation_Classical // GenMAPP -2.43 -2.63
TGF_Beta_Signaling_Pathway // GenMAPP -2.93 -2.64
Matrix_Metalloproteinases // GenMAPP -3.06 -2.65
Complement Activation, Classical Pathway // GO:0006958 -2.28 -2.67
Cell Differentiation // GO:0030154 -2.39 -2.71
GLUT_UP: Peng_at_al_2002 -3.26 -2.73
chr1q24: Cytogenetic band -2.87 -2.89
Matrix_Metalloproteinases: BioCarta -2.52 -2.95
RAP_UP: Peng_at_al_2002 -3.46 -2.99
Locomotory Behavior // GO:0007626 -2.28 -3.14
Transmembrane Receptor Protein Tyrosine Kinase Activity // GO:0004714 -2.66 -3.16
EMT_UP: Jechlinger_et_al_2003 -3.18 -3.21
Specific Rna Polymerase Ii Transcription Factor Activity // GO:0003704 -3.01 -3.24
RAR_UP: Manually Curated -3.08 -3.25
Response To Wounding // GO:0009611 -2.48 -3.28
Cell Motility // GO:0006928 -2.73 -3.29
Locomotion // GO:0040011 -2.7 -3.33
cell_adhesion -2.32 -3.34
classic complement pathway -2.77 -3.34
Vascular Endothelial Growth Factor Receptor Activity // GO:0005021 -2.56 -3.38
Transmembrane Receptor Protein Kinase Activity // GO:0019199 -3.09 -3.48
Immune Complement Pathway -3.25 -3.66
STTTCRNTTT: IRF:Interferon regulatory factor -3.55 -3.7
CR_IMMUNE_FUNCTION: PNAS_2009 -3.29 -3.72
Response To Virus // GO:0009615 -2.65 -3.85
Cell Adhesion // GO:0007155 -5.01 -4.05
Humoral Defense Mechanism // GO:0016064 -2.75 -4.37
Humoral Immune Response // GO:0006959 -2.93 -4.42
Antigen Processing // GO:0030333 -3.72 -4.49
morf1_34033_s_at_LILRB1: na -3.27 -4.66
Antigen Presentation // GO:0019882 -3.98 -5.87
Response To External Biotic Stimulus // GO:0043207 -2.73 -5.95
Response To Pest, Pathogen Or Parasite // GO:0009613 -2.87 -6.21
Immune Response // GO:0006955 -3.61 -6.49
T1* Score of differential expression (NT_k statistic as described in Tian et al[20].)BMC Medical Genomics 2008, 1:27 http://www.biomedcentral.com/1755-8794/1/27
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querying the same gene could obscure splice-variant-spe-
cific responses to estrogen, or dilute desirable signal with
poorly performing probe sets. Given the above caveats, it
is still encouraging that we find a significant positive cor-
relation in regulation between the two species, suggesting
similar underlying molecular mechanisms for estrogen
response. This study is also consistent with other valida-
tions of this animal model in the literature. OVX animals
have long been used to model the effects of estrogens on
the reproductive tract and skeleton, and have been vali-
dated through a number of different criteria, including
histology and response to clinically active agents.
While there is a significant positive correlation of the 17β-
estradiol response in rat and human, it should be noted
that the correlation is not perfect. There are many possible
technical reasons for the differences as described above.
To put this in perspective, we performed an identical anal-
ysis, where instead of comparing pre- vs post- estrogen
treatment, we compared kidney vs liver samples in each
species. A comparison between two very distinct tissues
represented an idealized dataset, where the results should
be the same for human and rat, and also a large degree of
differential expression is expected, due to tissue-specific
genes. In this regard, we considered the degree of agree-
ment between human and rat for this tissue comparison
to be the upper limit of what can be expected. The t-statis-
tic correlation between species was 0.48 (analogous to
Figure 2). While 0.48 is higher than the 0.33 we see in our
experiments, this is not very surprising since a treatment
response within a single tissue is a subtle effect, relative to
a comparison between two different tissues. Furthermore,
McCarroll et al. [29] studied the transcriptional response
to aging in flies vs. worms. They found a t-statistic correla-
tion 0.15 which they note to be highly significant. We
expect to have a higher correlation coefficient than 15%
since rat and human are evolutionarily closer than flies
and worms. Therefore, we feel the ~30% correlation coef-
Expression of BTC increases proliferation of vaginal epithelia Figure 5
Expression of BTC increases proliferation of vaginal epithelia. (A) Hematoxylin and eosin staining of vaginal epithelium 
from OVX rats treated with vehicle (V), 17β-estradiol (E2), betacellulin with normal histology (BTC) and betacellulin with 
abnormal histology (BTC-abn). (B) Rat BTC expression levels from microarray analysis at the 6 hour, 3 day and 5 day time-
points. (C) Human BTC expression levels from qRT-PCR analysis versus patient number.
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ficient is in the expected value range (between 15% and
48%).
We were initially surprised that the majority of genes reg-
ulated by 17β-estradiol were suppressed rather than stim-
ulated. Our assumption was that 17β-estradiol would
exert its pro-proliferatory activities primarily by upregulat-
ing genes. However, our data are in line with those
obtained from microarray studies done in MCF-7 breast
cancer cells, where estrogens also have a pro-proliferatory
effect: 70% of the regulated genes were suppressed [30].
Estrogen is the gold standard therapy for treatment of VA
and the identification of estrogen regulated genes in both
human and rat likely yields genes responsible for the
estrogenic effect. We have chosen to validate a gene that is
estrogen-responsive in both rat and human vaginal sam-
ples. Betacellulin is a member of the epidermal growth
factor family of peptide ligands and is a potent mitogen
for a wide variety of cell types affecting cell proliferation,
differentiation, survival and migration. Estrogens are
known to stimulate expression of other members of this
family, such as amphiregulin [30]. It has functional
redundancy to other members of the EGF family [27]. The
increased epithelial thickening seen in the OVX vagina is
consistent with its mitogenic role and suggests that BTC
may have a normal role in estrogen-dependent epithelial
maintenance. Additionally, BTC is able to stimulate mam-
mary gland differentiation as well as promote the survival
of breast cancer cell lines [31,32]. However, the uncon-
trolled proliferation seen in the OVX treated vagina sug-
gests that 17β-estradiol may be regulating other factors to
control BTC's mitogenic effect.
Conclusion
Here we have identified estrogen-regulated genes in the
vagina of humans and a commonly used rat animal
model. In addition to demonstrating that the vagina is a
highly estrogen-responsive organ at the molecular level,
we show that the transcriptional response to estrogen is
highly correlated between the two species. Furthermore,
we hypothesized that genes with estrogen-sensitivity in
both species are more likely to be responsible for the
changes observed in estrogen treated OVX rats. We have
shown that BTC, a gene regulated by estrogen in both
human and rat, does in fact have the ability to recapitulate
the estrogen induced epithelial proliferation. It is likely
that many other genes also possess the ability to induce
epithelial proliferation and current investigations are
underway to identify them.
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